A majority (> 85%) of the R/R FLT3-mutated AML patients treated in the gilteritinib and quizartinib phase II/III trials were prior FLT3 inhibitor naïve [4–13], a population that is quickly becoming obsolete with increased testing and appropriate widespread addition of midostaurin (or sorafenib where midostaurin is not yet available) to frontline induction in patients with FLT3-mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.